|
|
 |
|
Viewing report
|
|
|
|
Stem Cell Therapy for Stroke
BioPolaris, Jan 2010, Pages: 35
Currently there is no effective therapeutic approach to reverse the brain damage caused by stroke because adult brain cells have limited ability for self-repair and spontaneous axonal regeneration.
At the first glance, the repair of human brain after stroke appears unrealistic as there is a loss of countless number of neurons and glial cells. The functional improvement after stroke requires neuro-restorative process that includes neurogenesis, angiogenesis and synaptic plasticity, or ability of the connection between two neurons to change its strength. Stem cell therapy has the potential to induce all three neuro-restorative processes and to facilitate functional recovery offering a new approach to regenerate damaged brain tissue in stroke patients. However, in comparison to stem cell-based therapy for other indications, such as cardiac diseases, peripheral arterial disease, diabetes and even spinal cord injury, the number of preclinical research or clinical studies in patients with stroke is very limited. This is the reason that there is still uncertainty in selection of the best type of stem cells for cellular grafts in stroke, or understanding of mechanisms involved in functional recovery and structural reorganization of damaged brain.
When considering stem cell therapy for the treatment of stroke, it is important to remember that brain is a very complex structure containing a maze of various cells, neuronal extensions, electrical signals and chemical transmissions, presenting extremely difficult task for its regeneration and functional recovery.
To be efficient, stem cell-based therapies for stroke are expected to fulfill two goals: they have to provide better circulation in brain through angiogenesis or neoangiogenesis, and to regenerate lost brain tissue.
The Stem Cell Therapy for Stroke report shows pipeline that contains only eight R & D products undergoing development by 11 companies. Out of eight products only one product is in Phase III clinical trials and for one product the Investigational New Drug (IND) application is approved. Further analysis reveals that this R & D pipeline is the most conservative when compared to stem cell therapeutic R & D pipelines for the treatment of cardiac diseases, peripheral arterial disease, diabetes and spinal cord injury. The majority (87%) of stem cells used for the treatment of spinal cord injury are mesenchymal stem cells and mesenchymal-like stem cells, which are undifferentiated in 88% of those products. Autologus stem cells, obtained from patient’s own tissues are used only in 37% of all products and embryonic-derived stem cells were not used in any of products undergoing development for the treatment of stroke
Customers who bought this item also bought
Stem Cell Therapy for Spinal Cord Injury
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Stem Cell Therapy for Peripheral Arterial Disease
Stem Cell Therapy for Cardiac Diseases
Stem Cell Therapy Perspectives in Treating Motor Neuron Diseases: ALS and SMA
Cell and Stem Cell Therapies for Diabetes
Drug Delivery in Cancer - Technologies, Markets and Companies
Cardiovascular Drug Delivery - Technologies, Markets and Companies
Regenerative Medicine Markets
Global Stem Cell and Advanced Technologies Market
|
|
|
|
